基于livertox数据库的药物说明书乙型肝炎再激活风险警示标注情况调查分析

肝脏 ›› 2024, Vol. 29 ›› Issue (1): 81-84.

基于livertox数据库的药物说明书乙型肝炎再激活风险警示标注情况调查分析

吴玲, 魏龙, 苏琼丽

412007 湖南株洲市中心医院药学部

收稿日期:2023-05-09 出版日期:2024-01-31 发布日期:2024-03-01
通讯作者: 苏琼丽,Email:suqiongli151@163.com

Analysis of hepatitis B reactivation risk warning label in drug instructions based on livertox database

WU Ling, WEI Long, SU Qiong-li

Department of Pharmacy, The Affifiliated Zhuzhou Hospital Xiangya Medical College CSU, Hunan 412007, China

Received:2023-05-09 Online:2024-01-31 Published:2024-03-01
Contact: SU Qiong-li,Email:suqiongli151@163.com

摘要/Abstract

摘要： 目的调查和分析996种药物HBV再激活(HBV reactivation,HBVr)在livertox数据库的记录情况与药品说明书中HBVr用药警示信息进行对比分析。方法统计livertox数据库中药物的HBVr提示信息,并与丁香园用药助手系统中收录的药品说明书HBVr用药警示信息标注进行对比。结果 livertox数据库中共有47个药物和1类药物有HBVr风险信息提示并已在我国上市。其中糖皮质激素类药物和10个药物说明书并无HBVr风险信息提示,有2个药物部分说明书有提示,部分没有。结论药品生产企业及时修订药品说明,根据最新信息增加警示标语。临床医师及药师在临床使用中,需加强对病毒性感染患者的用药监护。

关键词: livertox, 药物性肝损伤, HBV再激活, 病毒性肝炎

Abstract: Objective To investigate and analyze the record of 996 drugs associated with hepatitis B reactivation (HBVr) documented in the livertox database, and to compare this information with the HBVr medication warnings provided in the drug instructions. Methods The HBVr prompt information of drugs in the Livertox database was counted and compared with the HBVr medication warning information in the drug instructions included in the DRUGS.dxy.cn. Results The Livertox database contained information on 47 drugs and 1 drug class, all of which had HBVr risk information prompts and were marketed in China. It was concerning to note that glucocorticoid drugs and 10 drug instructions did not mention HBVr risk information, while 2 drug instructions only partially mentioned the risk. Conclusion Drug manufacturer should promptly update drug descriptions and add warning labels based on the latest HBVr risk information. Clinicians and pharmacists need to enhance medication monitoring for patients with viral infection to promote safe drug use.

Key words: Livertox, Drug-induced liver injury, HBV reactivation, Hepatitis B

吴玲, 魏龙, 苏琼丽. 基于livertox数据库的药物说明书乙型肝炎再激活风险警示标注情况调查分析[J]. 肝脏, 2024, 29(1): 81-84.

WU Ling, WEI Long, SU Qiong-li. Analysis of hepatitis B reactivation risk warning label in drug instructions based on livertox database[J]. Chinese Hepatolgy, 2024, 29(1): 81-84.

参考文献

[1] 钟霄,周鹏程,范学工.乙型肝炎病毒再激活概述[J].中国感染控制杂志,2017,16(11):1089-1094.
[2] 蔡庆贤,罗芳,夏章,等.常见抗肿瘤药物所致乙型肝炎病毒再激活的诊疗进展[J].临床内科杂志,2022,39(07):439-444.
[3] Liver Tox:Clinical and Research Information on Drug-Induced Liver Injury[M].Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.https://www.ncbi.nlm.nih.gov/books/NBK547852/
[4] 唐婧,宋微微,艾超.药品说明书中肝功能不全患者用药警示信息标注情况调查分析[J].中国现代应用药学,2020,37(07):873-876.
[5] 尤红,王福生,李太生等.慢性乙型肝炎防治指南(2022年版)[J].实用肝脏病杂志,2023,26(03):457-478.
[6] Papalopoulos I, Fanouriakis A, Kougkas N, et al. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study[J]. Clin Exp Rheumatol, 2018,36:102-109.
[7] ZHANG S,JI D,CHEN GF.An excerpt of APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy ( 2021) [J]. J Clin Hepatol,2021,37( 12) : 2782-2786.
[8] 陈宛丽,姚金晓,杨莹,王舒,刘冰.弥漫大B细胞淋巴瘤患者化疗后HBV再激活的影响因素[J].中华医院感染学杂志,2022,32(18):2803-2807.
[9] 王汇敏,包俊豪,何美芝,等.恩替卡韦和拉米夫定防治血液肿瘤化疗后乙型肝炎病毒再激活的临床研究[J].中国实用内科杂志,2020,40(08):668-670.
[10] Moneva-Leniz LM,Sahuquillo-Torralba A,Vila-Payeras A,et al.Risk of hepatitis B virus reactivation in patientson secukinumab for psoriasis:a series of 4 cases[J].Acta sDermosifiliogr(EnglEd),2020,111(7):613-614.
[11] Chiu HY, Hui RC, Huang YH, et al.Safety profile of secukinumab in treatment of patients with psoriasisand concurrent hepatitis B or C:a multicentric prospective cohort study[J].Acta Derm Venereol,2018,98(9):829-834.
[12] 王惠,凌青霞,庄一心.非小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂治疗中乙肝再激活发生率[J].中国肿瘤临床与康复,2022,29(02):134-137.
[13] Carr A,Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patienton protease inhibitor[J].Lancet,1997,349:995-6.
[14] 雷定佳,秦波.免疫检查点抑制剂相关乙型肝炎病毒再激活研究进展[J].肝脏,2022,27(10):1135-1138.
[15] Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition[J]. J Immunother Cancer, 2019, 7(1):322.
[16] 何林蓉,葛勇鹏,李嗣钊,等.风湿病患者发生传统免疫抑制剂相关乙肝病毒再激活的认识[J].中日友好医院学报,2019,33(05):303-305.
[17] Mo YQ, Liang AQ, Ma JD, et al. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice[J]. BMC Musculoskelet Disord, 2014, 15: 449.
[18] Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives[J]. Eur J Cancer, 2017 Dec;87:101-112.
[19] 耿研,谢希,王昱,等.类风湿关节炎诊疗规范[J].中华内科杂志,2022,61(01):51-59.